Larimar Therapeutics (STU:ZA71) Total Current Assets : €153.07 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Larimar Therapeutics's total current assets for the quarter that ended in Mar. 2025 was €153.07 Mil.

Larimar Therapeutics Total Current Assets Historical Data

The historical data trend for Larimar Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Total Current Assets Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

80.52

63.90

113.98

82.69

186.52

Larimar Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															212.48	214.72	192.14	186.52	153.07

Larimar Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Larimar Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	175.199	+	1.007	+	0	+	10.309
	=	186.52

Larimar Therapeutics's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	145.712	+	0.977	+	0	+	6.385
	=	153.07

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Larimar Therapeutics (STU:ZA71) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Larimar Therapeutics's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	145.712	-	23.961	+	0.75 * 0	+	0.5 * 0
=	121.75

Larimar Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

LRMR:USA

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines